INTRODUCTION
This technical report describes the evidence base for the American Academy of Pediatrics' policy statements "Public Policy to Protect Children From Tobacco, Nicotine, and Tobacco Smoke" and "Clinical Practice Policy to Protect Children From Tobacco, Nicotine, and Tobacco Smoke". 1, 2 The goal of the present technical report is to document knowledge regarding the harms of tobacco to children and adolescents and to document the evidence for actions by clinicians and policy makers to reduce the toll that tobacco takes on children and adolescents. Because comprehensive literature reviews and evaluations are conducted by the Office of the Surgeon General, the present report focused on additional research findings subsequent to the Reports of the Surgeon General and topics not well covered in those reports. When multiple studies produced similar findings, the best quality and/or most recent are presented with reference to meta-analyses or authoritative statements (eg, Reports of the Surgeon General, US Public Health Service recommendations or guidelines) when available. Relevant literature was identified by using PubMed searches and references cited in relevant review articles or authoritative statements. Each article was assessed for quality and relevance. Reports of the Surgeon General were identified from the Web site http://www.surgeongeneral.gov/ library/reports/index.html.
GRADING EVIDENCE ON THE HARMS OF TOBACCO
Because it is unethical to conduct randomized controlled clinical trials among children with a substance that is harmful, the evidence related to the harms of tobacco has been graded as follows: strong quality-consistent findings from double-blind, randomized controlled clinical trials, large representative-sample epidemiologic studies, good-quality meta-analyses incorporating large representative studies with consistent results, and/or a Report of the Surgeon General of a "major conclusion" or "evidence is sufficient"; good quality-well-performed, generalizable case-control study, other well-performed epidemiologic study, other meta-analyses, and a Report of the Surgeon General of "evidence is suggestive"; or fair quality-other research study, small sample size, and findings not replicated.
GRADING EVIDENCE FOR CLINICAL AND POLICY RECOMMENDATIONS
Evidence quality and strength of recommendations were determined on the basis of guidelines of the American Academy of Pediatrics' policy statement "Classifying Recommendations for Clinical Practice Guidelines" and are summarized in Fig 1 and Table 1 . 3 
DEFINITIONS
• Tobacco product: any nicotine delivery product, currently regulated or unregulated by the US Food and Drug Administration (FDA), which is not approved for safe and effective tobacco dependence treatment.
• Secondhand smoke: the smoke emitted from a tobacco product that is inhaled by a nonuser.
• Thirdhand smoke: the tobacco smoke that is absorbed onto surfaces and exposes the nonuser by either direct contact and dermal absorption and/or off-gassing and inhalation. Thirdhand smoke may react with oxidants and other compounds in the environment to yield secondary pollutants. 4 • Involuntary tobacco smoke exposure: the tobacco smoke exposure of nonusers. Involuntary exposure includes both secondhand and thirdhand exposure.
• Electronic nicotine delivery systems: handheld devices that produce an aerosol from a solution typically containing nicotine, flavoring chemicals, and carrier solvents such as propylene glycol and vegetable glycerin (glycerol) for inhalation by the user. Alternate names for these products include electronic cigarettes, e-cigarettes, e-cigs, electronic cigars, e-cigars, electronic hookah, e-hookah, hookah sticks, personal vaporizers, mechanical mods, vape pens, and vaping devices. Tobacco-dependent parents and caregivers are important sources of children's tobacco smoke exposure. A total of 519 children aged 3 to 12 years with a history of asthma and tobacco smoke exposure were enrolled in a clinical trial of an intervention for reducing tobacco smoke exposure. 13 The ratio of urine cotinine to creatinine was higher if either the mother or caregiver were tobacco smokers and highest if both were smokers. 46 An ecologic study in Belgium found that after introduction of staged smoke-free legislation (first workplaces, then restaurants, then bars that serve food), rates of preterm birth decreased, with further decreases in preterm birth rates with each successive escalation of the smoking restrictions. 47 Similar reductions in preterm birth were observed coinciding with the implementation of smoke-free legislation in Scotland. 48 7. Tobacco increases infant mortality. 54 Among 466 children enrolled in the CHIRAH (Chicago Initiative to Raise Asthma Health Equity) study, increases in salivary cotinine concentrations were associated with an increased risk of asthma exacerbations. 55 Implementation of smoke-free legislation led to decreases in childhood asthma hospitalizations in England and Scotland. 56, 57 9. The effects of tobacco smoke exposure on risk of asthma start in utero.
KEY FINDINGS How Tobacco Harms Children

Quality of evidence: strong
Prenatal tobacco smoke exposure adversely affects lung development. In a cohort of 4574 mothers and their children prospectively followed up from pregnancy through the first 4 years of the child's life, exposure to maternal smoking when in utero as well as secondhand smoke after birth were associated with increased risk for wheezing at 2 to 4 years of age. 58 History of in utero tobacco smoke exposure was associated with greater rates of poor asthma control in 2481 Latino and African-American children with asthma when assessed at 8 to 17 years of age. 59 A prospective followup study of 1129 children from birth to 14 years of age found that maternal smoking during pregnancy was associated with current asthma, current wheeze, and exercise-induced wheeze 78 A survey of 5494 preschool-aged children in Bavaria, Germany, confirmed that a history of secondhand tobacco smoke exposure was associated with an increase in conduct problems and hyperactivity/ inattention that was independent of the effect of maternal smoking before and during pregnancy. 79 The Generation R Study enrolled mothers early in pregnancy and observed them and their children prospectively. 80 Maternal smoking and smoke exposure were assessed during pregnancy, and child behavior problems were assessed at 18 months for 4329 mother-child dyads. Maternal smoking during pregnancy and paternal smoking were both associated with increased behavior problems for the child; however, these findings were not robust to statistical adjustment for psychosocial variables. A study in Finland of administrative data on 175 869 children born 1987 through 1989 found that maternal smoking increased the risk of having a psychiatric diagnosis through 18 years of age in analyses controlling for maternal psychiatric diagnosis and child's gender. 81 A birth cohort study in Brisbane, Australia, assessed maternal smoking starting at the first prenatal visit. 82 15. Tobacco smoke exposure of children leads to findings of preclinical atherosclerosis.
A cohort of 545 children in Finland prospectively followed up from infancy through adolescence had serum cotinine concentrations measured annually between 8 and 13 years of age. 85 Carotid intima-media thickness was greater and peak flow-mediated dilation of the brachial artery was lower in children in the highest tertile of tobacco smoke exposure. Similar results were found in a study of 16-year-old male adolescents (N = 610) in Lhasa City, Tibet, 86 and in a case-control study of healthy young adults. 87 Using pooled data from the Cardiovascular Risk in Young Finns study (Finland) and the Childhood Determinants of Adult Health study (Australia), exposure to parental smoking was assessed in 3416 children and carotid intimamedia thickness was assessed in adulthood, 21 to 28 years later. If both parents smoked at baseline, the child's carotid intima-media thickness in adulthood was greater (mean: 0.652 vs 0.637 mm; P = .003 in fully adjusted analyses). 88 This study did not find that smoking by 1 parent had an effect; however, the study did not differentiate maternal from paternal smoking. This omission may be important because maternal smoking generally has a greater effect on a child's level of tobacco smoke exposure. 13 Soluble intercellular adhesion molecule 1 (s-ICAM1) is a measure of endothelial stress, and hair cotinine is a biomarker of tobacco smoke exposure. In a sample of children aged 9 to 18 years in Columbus, Ohio, hair cotinine concentrations were positively correlated with s-ICAM1 levels. 89 A substantial amount of the variance in s-ICAM1 was accounted for by hair cotinine level of the child (partial R 2 = 0.26, P = .0001 for the association of log hair cotinine with s-ICAM1 level in multivariate models adjusting for BMI, age, mean blood pressure, and very low-density lipoprotein level). 93 17. Smoke-free homes may reduce children's tobacco smoke exposure.
Quality of evidence: good
Smoke-free homes and cars may reduce children's tobacco smoke exposure but are unlikely to completely protect a child as long as household members are smokers. A randomized controlled trial of an intensive intervention to implement smoke-free homes in Ankara, Turkey, found substantial reductions in urine cotinine levels over 12 months of follow-up in the intervention group but not in the control group. 94 A randomized controlled study among Latino families in Houston, Texas, in which an adult was a smoker compared provision of 2 culturally appropriate fotonovelas (illustrated storybooks) and 1 comic book, which were designed to promote a tobaccofree indoor environment, versus use of a standard smoking cessation guide published by the American Cancer Society. At the 12-month follow-up, there were more reported bans on in-home smoking for the intervention (fotonovela) condition (73% vs 56%). Although the results did not differ according to intervention group, those homes with an in-home smoking ban had reduced nicotine concentrations on the home surfaces sampled (0.04 6 0.04 mg/m 3 vs 0.47 6 0.66 mg/m 3 ; P , .01). 95 A study in Columbus, Ohio, of children younger than 3 years found that when the mother was a smoker, hair cotinine concentrations were not significantly different if the mother reported smoking inside or outside. 96 18. Tobacco dependence almost always develops before reaching the age of majority.
Quality of evidence: strong
Tobacco is a substance of abuse. The 2012 Report of the Surgeon General concluded, "Given their developmental stage, adolescents and young adults are uniquely susceptible to social and environmental influences to use tobacco," and "Among adults who become daily smokers, nearly all first use of cigarettes occurs by 18 years of age (88%), with 99% of first use by 26 years of age." 4 Nicotine dependence develops early and drives the progression from intermittent to daily smoking. A study of 1246 English-speaking students from central Massachusetts enrolled students in sixth grade and monitored them prospectively for 4 years. 97, 98 Of the 370 subjects who had inhaled from a cigarette, the median age at first cigarette use was 12 years. At least 1 symptom of early nicotine dependence was reported by 33% of participants who had ever puffed on a cigarette. Experiencing any symptom of nicotine dependence increased the risk of progressing to monthly smoking (adjusted hazard ratio: 3.7 [95% CI: 2.4-5.5]) or daily smoking (adjusted hazard ratio: 6.8 [95% CI: 4.4-10.5]). Analyses of data from the 2004 NYTS found that among the 2580 adolescent smokers aged 12 to 18 years who participated in the survey, there was a strong correlation between nicotine withdrawal symptoms and both the amount and frequency of smoking. 99 19. Tobacco dependence is a treatable chronic illness. 102 Combination nicotine replacement therapy outperformed single formulations. Forms of nicotine replacement therapy that are approved by the FDA for tobacco dependence treatment are nicotine patches, nicotine gum, and nicotine lozenges (available over the counter in the United States) as well as nicotine nasal spray and nicotine inhalers (available only by prescription in the United States).
The 2009 American College of Chest Physicians' Tobacco Dependence Treatment ToolKit advises, "Approaching tobacco dependence as a chronic disease acknowledges the altered central nervous system (CNS) neurobiology in tobacco-dependent patients. The goal of therapy in tobacco dependence is to normalize brain function-so that the patient has minimal to no symptoms of nicotine withdrawal, thus allowing the patient to feel (near) normal while not using tobacco. The intensity of treatment should be based on the severity level of nicotine dependence. For highly nicotine-dependent patients, combination therapy is often needed." 103 Adhering to the model of asthma and other chronic diseases regarding exacerbations and remissions, the longer acting medications can be thought of as "controllers," with the faster acting medications used as "relievers."
In studies of tobacco-dependent adults, initiation of nicotine replacement therapy before stopping smoking improves the effectiveness of treatment. A multisite, randomized clinical trial with parallel groups (placebo and active treatmentcontrolled) included 400 tobaccodependent adult subjects in North Carolina. 104 It provided an intervention of a 21-mg nicotine patch versus placebo daily for 2 weeks before cessation, with active nicotine patch (no placebos) provided for all subjects after the stop smoking date. Precessation treatment with the nicotine patch substantially improved quit rates, with the greatest benefit for those with lower levels of nicotine dependence ( 105 For further details on practical, evidence-based, expert consensus recommendations for tobacco dependence treatment, the reader is referred to the American College of Chest Physicians' Tobacco Dependence Treatment ToolKit (http://tobaccodependence.chestnet. org).
RECOMMENDED ACTIONS FOR PEDIATRICIANS
1. Inquire about tobacco use and tobacco smoke exposure as part of health supervision visits and visits for diseases that may be caused or exacerbated by tobacco smoke exposure. Evidence quality: B
Recommendation strength: strong recommendation
It is important to identify tobacco use so that appropriate interventions can be offered to prevent tobacco use initiation, recommend stopping smoking, and/ or recommend treatment of tobacco dependence. It is important that tobacco smoke exposure be identified so that interventions can be offered to reduce this exposure. The Memphis Health Project, a longitudinal study of smoking in 5154 adolescents, found that participants who were both screened and advised had more knowledge about the health risks of smoking and more negative perceptions of the social value of smoking than participants with no intervention or screening. 106 The US Preventive Services Task Force (USPSTF) recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use in school-aged children and adolescents. 109 The USPSTF report concluded, "The USPSTF found adequate evidence that behavioral counseling interventions, such as face-to-face or phone interaction with a health care provider, print materials, and computer applications, can reduce the risk for smoking initiation in school-aged children and adolescents." A meta-analysis of behaviorally based interventions to prevent tobacco use initiation found 10 relevant trials with a pooled risk ratio of 0.81 (95% CI: 0.70-0.93). 110 3. Address parent/caregiver tobacco dependence as part of pediatric health care. Evidence quality: B
Because tobacco smoke exposure is harmful to the child, and parental tobacco smoking is an important source of a child's tobacco smoke exposure, addressing parental and caregiver tobacco dependence is important in protecting the health of the child. According to the US Public Health Service-sponsored evidencebased guideline Treating Tobacco Use and Dependence: 2008 Update, "It is essential that clinicians and health care delivery systems consistently identify and document tobacco use status and treat every tobacco user seen in a health care setting." 100 An assessment of parents of tobacco smoke-exposed children with asthma who enrolled in a clinical trial found that most of the primary caregivers who were tobacco smokers were interested in stopping smoking; 56.5% were at the contemplation or better stage of change. 13 Tobacco dependence treatment or recommendation for treatment by pediatricians is acceptable to most parents. A nationally representative (US) telephonic survey included 730 parents who had accompanied a child to a health care visit in the past year, of whom 21% were tobacco smokers. 111 The survey found that most (59.7%) of the smokers thought it would be acceptable to have the child's physicians prescribe or recommend a tobacco dependence treatment medication for them.
3a. Recommend tobacco dependence treatment of tobacco-dependent parents and caregivers. Evidence quality: B Recommendation strength: strong recommendation
According to the US Public Health Service-sponsored evidence-based guideline Treating Tobacco Use and Dependence: 2008 Update, "Counseling and medication are effective when used by themselves for treating tobacco dependence. The combination of counseling and medication, however, is more effective than either alone. Thus, clinicians should encourage all adults making an attempt to stop tobacco to use both counseling and medication." 100 Behaviorally based interventions for parental tobacco dependence have limited benefit; interventions that include use of medications show greater efficacy. A clinical trial of cotinine feedback and behavioral counseling for parents of tobacco smoke-exposed children with asthma found no significant intervention effect; however, on subgroup analyses, children with high-risk asthma who received the intervention had a greater reduction in the ratio of urine cotinine to creatinine than did the control group. 112 A meta-analysis of studies designed to protect children from tobacco smoke exposure through parental cessation or modification of parental smoking identified 18 relevant studies published through March 2011. 113 Studies had substantial variation in the methods and interventions tested. The relative risk of parental smoking cessation from the pooled study results was 1 114 The intervention included: (1) routine screening for parental tobacco use; (2) motivational messaging based on the parents' own concerns; and (3) recommendation and possible provision of nicotine patch and gum by the clinician and enrollment in the free state (telephone) quitline. On exit interview, parental smokers in the intervention practices reported a higher rate of discussing methods to stop smoking (24% vs 2%; P , .001), prescription of nicotine replacement medication (12% vs 0%; P , .001), and enrollment in the state (telephonic) quitline (10% vs 0%; P , .001).
Before prescribing tobacco dependence treatment for parents, pediatricians should verify that their medical liability insurance provides coverage for care offered to adults. If the pediatrician elects to prescribe for parents, he or she should conduct an appropriate assessment of disease (tobacco dependence), consider possible contraindications to the medications, counsel about risks and benefits, offer recommendations for follow-up, and provide appropriate treatment. Follow-up is important to 118, 119 There is emerging evidence documenting a benefit of pharmacotherapy for tobaccodependent adolescents; adherence is challenging, however, and relapse after brief courses of treatment is common. Investigators compared the use of a nicotine patch versus nicotine gum versus placebo in a randomized, double-blind, placebocontrolled clinical trial with 120 adolescents who wanted to stop smoking and had moderate or greater tobacco dependence. 120 Medication was initiated on the planned stopsmoking day and continued for 12 weeks. Group cognitive behavioral therapy was provided to all participants. At 1 week after the stopsmoking date, 26.5% of those receiving the nicotine patch, 17.4% of those receiving the nicotine gum, and 5.0% of the placebo group were not smoking (P = .02 for patch versus placebo). By 3 months after pharmacotherapy was discontinued, nonsmoking rates were 20.6% for the patch, 8.7% for the gum, and 5% for placebo (P = .06 for patch versus placebo). Adherence to daily use of the patch was acceptable at 78.4%; adherence to use of the nicotine gum was poor at 38.5%. Analyses of trial participants who had stopped smoking and then restarted found that those who restarted smoking after a period of abstinence had greater craving scores, suggesting that inadequately controlled withdrawal contributed to the lapse. 121 A randomized, doubleblind, placebo-controlled, parallelgroup clinical trial included 6 weeks of bupropion plus counseling for tobacco-dependent adolescents. 122 The authors found improved rates of smoking cessation with 150 mg of bupropion twice daily when the medication was being taken (29% abstinent at 6 weeks with bupropion vs 16% with placebo [P = .02]); the benefit was quickly lost after the medication was stopped, however.
Because there has been limited research on tobacco dependence pharmacotherapy in adolescents, the FDA-approved labeling for these medications states, "Safety and effectiveness in the pediatric population have not been established." Because tobacco dependence is a severe chronic illness that debilitates, harms offspring, and shortens life, it is reasonable to consider that pharmacotherapy documented as effective in adults is an option for the treatment of adolescents with moderate to severe tobacco dependence. Given the high rates of nonadherence during therapy and relapse after discontinuation of therapy among adolescents in the trials of these medications, close follow-up is recommended.
Offer tobacco-dependent individuals quitline referral. Evidence quality: A Recommendation strength: strong recommendation
Studies among adults found that free (to the user) telephonic tobacco dependence treatment is beneficial; however, research among teenagers
is not yet available, and the services provided vary substantially. Callers to the California Smokers' Helpline during periods of high call volume who were ready to stop smoking were randomized to be immediately assigned to a counselor (treatment) or asked to call back (control). 123 All callers were sent written selfhelp materials. Twelve-month abstinence rates were 9.1% in the treatment group versus 6.9% in the control group (P , .001), with the entire difference in the control group attributable to those members who did not call back to receive assistance. A recent Cochrane review of telephonic counseling for smoking cessation found 77 trials that met inclusion criteria. 124 Among smokers who contacted helplines, quit rates were higher for groups randomized to receive multiple sessions of proactive counseling (9 studies, .24 000 participants; relative risk for cessation at longest follow-up: 1.37 [95% CI: 1.26-1.50]).
6. Consider potential for neuropsychiatric symptoms with tobacco dependence treatment.
Evidence quality: C
Recommendation strength: recommendation
Pediatricians should be aware of the increased risk of suicidal ideation and suicide, both among continuing smokers and among those being treated for tobacco dependence. In studies among adults, suicide is associated with cigarette use in a dose-dependent manner. [125] [126] [127] Studies of adolescent population samples and youth with bipolar disorder demonstrate an association between tobacco use and suicide risk. 128, 129 In postmarketing surveillance, suicidal ideation and suicide have been reported among patients taking varenicline and bupropion, with a black box warning issued by the FDA for both medications. 130 A study of 119 546 adults in England who used a smoking cessation product found no differences in rates of treated depression, nonfatal self-harm, and fatal self-harm within 3 months of the first smoking cessation prescription; the study compared those who received varenicline or bupropion with those who received nicotine replacement. 131 Neuropsychiatric symptoms associated with tobacco dependence treatment may reflect inadequate control of nicotine withdrawal. 103 Comorbidities of substance abuse and psychiatric disorders may accompany tobacco dependence 14 and can make tobacco dependence more difficult to treat. These comorbidities, when identified, should be addressed through appropriate referral.
The risk of treatment-emergent neuropsychiatric symptoms should be balanced against the substantial harms of continued tobacco use. As with any other prescribing, the discussion of risks versus benefits should be documented in the health record.
7. Do not recommend electronic nicotine delivery systems for tobacco dependence treatment.
Evidence quality: B
Recommendation strength: strong recommendation
Electronic nicotine delivery systems have not been shown to be effective for smoking cessation. 132 There is currently no regulation on content or manufacturing standards for electronic nicotine delivery systems.
In addition to nicotine, carcinogens, toxins, metals, and silicates have been found in the emissions from these devices. [133] [134] [135] The adverse effects of long-term inhalation of the flavoring agents used is not known, and some commonly used agents are known respiratory irritants. 136 Pediatricians should direct patients who want pharmacotherapy for tobacco dependence to therapies that have been documented to be effective and are approved as such by the FDA. In New Zealand, a clinical trial of e-cigarettes for smoking cessation among moderately to severely tobaccodependent adults found low cessation rates and no statistically significant difference between the use of nicotine-containing e-cigarettes and placebo. 137 Among adolescents, the use of e-cigarettes is associated with decreased rates of stopping smoking. A nationally representative survey of middle and high school students in Korea found that among current adolescent smokers, although there were more attempts to stop smoking among e-cigarette users (OR: 1.67 [95% CI: 1.48-1.90]), current e-cigarette users were much less likely to have stopped using cigarettes (OR: 0.10 [95% CI: 0.09-0.12]) compared with smokers who never used e-cigarettes. 138 An analysis of 2011 and 2012 NYTS data found that among smokers (having smoked at least 100 cigarettes in their lifetime) who had ever used e-cigarettes, both ever having used e-cigarettes and current e-cigarette use were associated with lower rates of abstinence from cigarette smoking A randomized, single-blind study of 352 children aged 8 to 16 years in Ankara, Turkey, tested a smoke-free home intervention aimed at increasing household smoking bans and reducing secondhand smoke exposure. Those randomized to the smoke-free home intervention had greater rates of in-home smoking restrictions and substantially lower urine cotinine levels at 2, 6, and 12 months of follow-up. 94 A randomized, single-blind study in 91 MexicanAmerican households used low literacy fotonovelas and a comic book to promote a tobacco-free indoor air environment. 95 The study found that a greater proportion of households in the intervention group implemented bans on smoking inside of the home. Although the study found no differences in ambient nicotine level according to intervention group, those households that implemented a ban on smoking indoors had lower ambient nicotine levels than households that did not implement such a ban.
A randomized single-blind study compared an in-home motivational interviewing intervention versus provision of written information by mail in households with children aged ,3 years and a parent/caregiver who is a smoker. 140 Ambient nicotine levels measured in the kitchen and the room with a television were lower in the motivational interviewing intervention group than in the written information control group.
A convenience sample of 291 children ages 2 weeks to 3 years was recruited from a clinic that serves predominantly low-income families in Columbus, Ohio. 96 Maternal smoking was reported in 41% of the sample. The report of an in-home smoking ban was associated with decreased hair cotinine levels, although the child's hair nicotine level did not differ regardless of whether the mother reported smoking outside only.
A single-blind, randomized controlled clinical trial of cotinine feedback plus behavioral counseling to reduce tobacco smoke exposure among tobacco smoke-exposed children with asthma in Northern California found no overall intervention effect; however, the subgroup of children with high-risk asthma had lower urine cotinine levels on follow-up. 112 PUBLIC POLICY RECOMMENDATIONS 1. The FDA should regulate all tobacco products to protect the public health.
Evidence quality: X
The FDA is charged with the mission of protecting consumers and enhancing public health by maximizing compliance of FDAregulated products and minimizing risks associated with those products. The FDA Center for Tobacco Products is responsible for carrying out the Family Smoking Prevention and Tobacco Control Act, passed in 2009 in an effort to protect the public and create a healthier future for all Americans. 141 This act puts in place restrictions on marketing tobacco products to children and gives the FDA the authority to take action in the future to protect public health. Some of the agency's responsibilities under the law include setting performance standards, reviewing premarketing applications for new and modified-risk tobacco products, and requiring new warning labels for tobacco products. 142 2. Tobacco control should be adequately funded. The CDC's Community Preventive Services Task Force evidence review found strong support for the effectiveness of comprehensive tobacco control programs in reducing tobacco use and secondhand smoke exposure, independent of increases in tobacco product prices or adoption of smoke-free policies. 144 These programs reduce the prevalence of tobacco use among adults and young people, reduce tobacco product consumption, increase quitting, and contribute to reductions in tobacco-related diseases and deaths. Increases in program funding are associated with increases in program effectiveness, with the greatest impact seen if programs are funded at CDC-recommended levels.
Tobacco control research should be considered a high priority and funded accordingly from both government and private sources. Tobacco industry funding should not be used for this purpose. The tobacco industry has a long history of using industry-funded programs to divert attention away from 156 Focus groups of adolescents in Auckland, New Zealand, found that graphic warning labels clearly prompted a more severe judgement of smokers' social appeal. 157 8. Tobacco product prices should be increased to reduce youth tobacco use initiation.
The US Task Force on Community Preventive Services (2001) strongly recommended increasing the unit price for tobacco products to reduce smoking initiation and reduce consumption of tobacco products. 158 Data from the Global Youth Tobacco Survey were matched to data on cigarette prices and estimated overall price elasticity (the relationship between demand for a product and its price) at -1.5; for low-and middleincome countries, however, price elasticity was greater at -2.2, suggesting that a 10% price increase would decrease youth smoking by 22%. 159 Increasing the tobacco tax has the benefit of both raising the price and providing a source of funds that can be used for tobacco control programs.
9. The minimum age to purchase tobacco should be increased to 21 years.
Evidence quality: B 3 . 182 An analysis of the content of the aerosol from e-cigarettes found toxic, irritating, and carcinogenic substances, including formaldehyde, acetaldehyde, and acrolein; volatile organic compounds such as toluene and m,p-xylene; tobacco-specific nitrosamines; and the heavy metals cadmium, nickel, and lead.
134
Recommendations to Protect Children From Acute Nicotine Poisoning 14. Children younger than 18 years should be legally prohibited from working on tobacco farms and in tobacco production.
Recommendation strength: recommendation
Green tobacco sickness is a welldescribed entity. Dermal absorption of nicotine from moist tobacco plants can lead to symptoms of severe nicotine poisoning, including weakness, headache, nausea, vomiting, dizziness, abdominal cramps, breathing difficulty, pallor, diarrhea, chills, fluctuations in blood pressure or heart rate, seizures, and increased perspiration and excessive salivation. 183 A report using Kentucky Regional Poison Control Center records in 1991 found 104 cases of green tobacco sickness; one-quarter of the reports were in children under 17 years. 184 A case series of 5 children with green tobacco sickness reported symptoms that included a seizure, bradycardia, vomiting, dizziness, headache, pallor, and/or muscle weakness. One child stated that it made him feel, "like I was going to die." 32 15. Concentrated nicotine solution for electronic nicotine delivery systems should be sold in child-resistant containers with amounts limited to that which would not be lethal to a young child if ingested.
Recommendation strength: strong recommendation
The colorful fruit-and candy-flavored concentrated nicotine solutions for use in electronic nicotine delivery systems can appeal to young children. The oral lethal dose of nicotine by body weight that is estimated to kill 50% of adults is projected to be between 0.8 and 13 mg/kg. 185 Severe nicotine toxicity in children has been reported with doses of nicotine as low as 2 mg. Calls to poison control centers for exposures to electronic nicotine delivery systems (with the majority occurring in children under 5 years) increased from 1 exposure call per month in September 2010 to 215 calls in February 2014. 186 The concentrated nicotine solution used in these devices is a poisoning risk for young children, and at least 1 child has already died of its accidental ingestion. 187 
CONCLUSIONS
Tobacco dependence starts in childhood. The tobacco epidemic takes a substantial toll on children's health, and the harm starts in utero. There is strong evidence to support actions by pediatricians and public policy decision makers that can reduce the development of tobacco dependence and reduce the tobacco smoke exposure of children.
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